Literature DB >> 31008566

Patient and Rheumatologist Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis.

Justin K Owensby1, Lang Chen1, Ronan O'Beirne1, Eric M Ruderman2, Leslie R Harrold3, Joshua A Melnick1, Monika M Safford4, Jeffrey R Curtis1, Maria I Danila1.   

Abstract

OBJECTIVE: To identify and prioritize patient- and rheumatologist-perceived barriers to achieving disease control.
METHODS: Patients with rheumatoid arthritis (RA) and rheumatologists from the Corrona registry were invited by e-mail to participate in nominal groups. Two separate lists of barriers were created, 1 from RA patient-only nominal groups and the other from rheumatologist-only nominal groups, and barriers were sorted into themes. Next, using an online survey, a random sample of RA patients from the Corrona registry were asked to rank their top 3 barriers to achieving disease control.
RESULTS: Four nominal groups totaling 37 RA patients identified patient barriers to achieving control of RA activity that were classified into 17 themes. Three nominal groups totaling 25 rheumatologists identified barriers that were classified into 11 themes. The financial aspects of RA care ranked first for both types of nominal groups, while medication risk aversion ranked second among the perceived barriers of the physician nominal group and third among those of the RA patient nominal group. Among the 450 RA patients surveyed, 77% considered RA a top health priority, and 51% reported being aware of the treat-to-target strategy for RA care; the 3 most important patient-perceived challenges to achieving disease control were RA prognosis uncertainty, medication risk aversion, and the financial/administrative burden associated with RA care.
CONCLUSION: There are common, potentially modifiable, patient- and rheumatologist-reported barriers to achieving RA disease control, including perceived medication risk aversion, suboptimal treatment adherence, and suboptimal patient-physician communication regarding the benefits of tight control of disease activity in RA. Addressing these obstacles may improve adherence to goal-directed RA care.
© 2020, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31008566      PMCID: PMC6810709          DOI: 10.1002/acr.23907

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  33 in total

1.  Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations.

Authors:  Leslie R Harrold; J Timothy Harrington; Jeffrey R Curtis; Daniel E Furst; Mary Jane Bentley; Ying Shan; George Reed; Joel Kremer; Jeffrey D Greenberg
Journal:  Arthritis Rheum       Date:  2012-03

2.  Routine Use of Quantitative Disease Activity Measurements among US Rheumatologists: Implications for Treat-to-target Management Strategies in Rheumatoid Arthritis.

Authors:  Jeffrey R Curtis; Lang Chen; Maria I Danila; Kenneth G Saag; Kathy L Parham; John J Cush
Journal:  J Rheumatol       Date:  2017-11-15       Impact factor: 4.666

3.  Decision tool to improve the quality of care in rheumatoid arthritis.

Authors:  Liana Fraenkel; Ellen Peters; Peter Charpentier; Blair Olsen; Lanette Errante; Robert T Schoen; Valerie Reyna
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-07       Impact factor: 4.794

4.  Rheumatoid Arthritis Patients' Motivations for Accepting or Resisting Disease-Modifying Antirheumatic Drug Treatment Regimens.

Authors:  Yomei Shaw; Ilinca D Metes; Kaleb Michaud; Julie M Donohue; Mark S Roberts; Marc C Levesque; Judy C Chang
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-03-11       Impact factor: 4.794

5.  Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2007-07

6.  High disease activity may not be sufficient to escalate care.

Authors:  Liana Fraenkel; Meaghan Cunningham
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-02       Impact factor: 4.794

7.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.

Authors:  Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen
Journal:  Arthritis Res Ther       Date:  2005-04-07       Impact factor: 5.156

8.  Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years.

Authors:  Nasir Wabe; Michael J Sorich; Mihir D Wechalekar; Leslie G Cleland; Leah McWilliams; Anita Lee; Llewellyn Spargo; Robert G Metcalf; Cindy Hall; Susanna M Proudman; Michael D Wiese
Journal:  Arthritis Res Ther       Date:  2015-03-08       Impact factor: 5.156

Review 9.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Authors:  Josef S Smolen; Ferdinand C Breedveld; Gerd R Burmester; Vivian Bykerk; Maxime Dougados; Paul Emery; Tore K Kvien; M Victoria Navarro-Compán; Susan Oliver; Monika Schoels; Marieke Scholte-Voshaar; Tanja Stamm; Michaela Stoffer; Tsutomu Takeuchi; Daniel Aletaha; Jose Louis Andreu; Martin Aringer; Martin Bergman; Neil Betteridge; Hans Bijlsma; Harald Burkhardt; Mario Cardiel; Bernard Combe; Patrick Durez; Joao Eurico Fonseca; Alan Gibofsky; Juan J Gomez-Reino; Winfried Graninger; Pekka Hannonen; Boulos Haraoui; Marios Kouloumas; Robert Landewe; Emilio Martin-Mola; Peter Nash; Mikkel Ostergaard; Andrew Östör; Pam Richards; Tuulikki Sokka-Isler; Carter Thorne; Athanasios G Tzioufas; Ronald van Vollenhoven; Martinus de Wit; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2015-05-12       Impact factor: 19.103

10.  Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register.

Authors:  James M Gwinnutt; Deborah P M Symmons; Alexander J MacGregor; Jacqueline R Chipping; Tarnya Marshall; Mark Lunt; Suzanne M M Verstappen
Journal:  Arthritis Rheumatol       Date:  2017-07-10       Impact factor: 10.995

View more
  3 in total

1.  Barriers, facilitators, preferences and expectations of joint protection programmes for patients with hand arthritis: a cross-sectional survey.

Authors:  Pavlos Bobos; Joy MacDermid; Christina Ziebart; Eleni Boutsikari; Emily Lalone; Louis Ferreira; Ruby Grewal
Journal:  BMJ Open       Date:  2021-01-22       Impact factor: 2.692

2.  Evaluation of an Intervention to Support Patient-Rheumatologist Conversations About Escalating Treatment in Patients with Rheumatoid Arthritis: A Proof-of-Principle Study.

Authors:  Maria I Danila; Lang Chen; Eric M Ruderman; Justin K Owensby; Ronan O'Beirne; Joshua A Melnick; Leslie R Harrold; David Curtis; W Benjamin Nowell; Jeffrey R Curtis
Journal:  ACR Open Rheumatol       Date:  2021-12-27

3.  Importance of Shared Treatment Goal Discussions in Rheumatoid Arthritis-A Cross-Sectional Survey: Patients Report Providers Seldom Discuss Treatment Goals and Outcomes Improve When Goals Are Discussed.

Authors:  Kelly D O'Neill; Kathryne E Marks; Pamela S Sinicrope; Cynthia S Crowson; Dana Symons; Elena Myasoedova; John M Davis
Journal:  ACR Open Rheumatol       Date:  2021-09-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.